Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00476905 · ClinicalTrials.gov registry record
Spectral Diagnosis of Cutaneous Malignancy
A clinical trial, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- 350
- Enrollment target
NCT00476905: Completed study, sponsored by M.D. Anderson Cancer Center.
NCT00476905 is a clinical trial that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 350 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00476905 has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- 350 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to evaluate the use of an imaging technology called spectral diagnosis. Researchers want to find out if a special spectral-diagnosis probe can be used to detect skin cancers.
Interventions
- DEVICE Spectral Diagnosis Probe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2007-04 |
| Est. Completion | 2018-11-20 |
What the finished NCT00476905 record still lists
NCT00476905 is an observational study that tracks outcomes without assigning an intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Spectral Diagnosis Probe is the first listed.
NCT00476905 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00476905 about?
NCT00476905 is a clinical study titled "Spectral Diagnosis of Cutaneous Malignancy". The goal of this clinical research study is to evaluate the use of an imaging technology called spectral diagnosis. Researchers want to find out if a special spectral-diagnosis probe can be used to detect skin cancers.
What is the current status of trial NCT00476905?
This trial is currently completed. The enrollment target is 350 participants. The study started on 2007-04. Estimated completion is 2018-11-20.
What interventions are being tested in trial NCT00476905?
The interventions under investigation include: Spectral Diagnosis Probe (DEVICE).
Who is sponsoring clinical trial NCT00476905?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia